

PO203860

Érvényes

Ügyszám: P0104993

MSZH e-lajstrom

Bejelentés napja: 1999.10.26

Közzététel napja: 2002.05.28

HU P0104993

Uniós elsőbbség: US60106739 - 1998.11.02

PCT bejelentés száma: US9925244

PCT közzététel száma (WO): 0025753

NSZO: A61K-009/24

Cím: Eljárás és eszköz hatóanyagok kontrollált bevitelére

Angol cím: METHOD AND DEVICE FOR CONTROLLED DELIVERY OF ACTIVE AGENTS


Bejelentő: ALZA Corporation, Mountain View, Kalifornia (US)

Feltaláló: Yam, Noymi, Sunnyvale, Kalifornia (US)

Bhatt, Padmanabh, Saratoga, Kalifornia (US)

Cruz, Evangeline G., Hayward, Kalifornia (US)

Képviselő: Szabó Zsolt, DANUBIA Szabadalmi és Védjegy Iroda Kft., Budapest (HU)

**Kivonat (közzétételi):**

A találmány tárgya hatóanyagot tartalmazó dózisforma (1), valamint kompresszált gyógyszerkészítményt, félígáteresztő falat (2) és tolófázist (5) tartalmazó dózisformából (1) hatóanyag ürülésének elősegítésére szolgáló eljárás.

A találmány szerinti dózisforma (1) tartalmaz üreget (3) meghatározó, legalább egy félígáteresztő tartománnyal és anyagában kialakított vagy kialakítható kiömlönyílással (4) rendelkező falat (2); az üregben (3) a kiömlönyílástól (4) távol a fal (2) félígáteresztő tartományával közlekedőn elrendezett tágulásra képes tolófázist (5); az üregben (3) a kiömlönyílással (4) szomszédosan, a tágulásra képes tolófázissal (5) közvetlenül vagy közvetve érintkezően elrendezett hatóanyagfázist (6); továbbá a fal (2) belső felülete és legalább az üregben (3) lévő hatóanyagfázis (6) külső felülete között elrendezett ürülést segítő fázist (7).

A találmány szerinti dózisforma ürülést segítő fázissal (7) bevont kompresszált gyógyszerkészítményt tartalmaz.

A szóban forgó eljárás lényege, hogy a félígáteresztő fal (2) és a kompresszált gyógyszerkészítmény között ürülést segítő fázist (7) rendeznek el.

\*\*\* ABRA Frame253 \*\*\*

\*\*\* ABRA Frame254 \*\*\*

**Intézkedések****4. Nemzetközi bejelentés közzététele (A2) (QJ)**

Intézkedés kelte: 2002.03.27 meghirdetése: 2002.05.28 (BB9A Szabadalmi bejelentések közzététele)

**9. Értesítés újdonságkutatás elvégzéséről (A3) (RV)**

Intézkedés kelte: 2003.01.27 meghirdetése: 2003.02.28 (EC9A Külön tájékoztatás újdonságkutatásról)

12. Ideiglenes szabadalmi oltalom újra érvénybe helyezése(2) (EI) ref.: 11  
Intézkedés kelte: 2003.06.25 átvétele: 2003.06.26 meghirdetése: 2003.07.28 (NF4A Szabadalmi oltalom újra érvénybe helyezése)

BEST AVAILABLE COPY

HU PO104 993

**THOMSON** **DELPHION** **RESEARCH** **PRODUCTS** **INSIDE DELPHION**

View: [Expand Details](#) Go to: [Delphion Integrated View](#)

No active trail [Select CR](#) [Stop Tracking](#)

My Account

## Derwent Record

Derwent Title: **Device for controlled delivery of high drug-loading compositions includes a flow-promoting layer between the semi-permeable layer and the drug layer**

Original Title: [WO0025753A2: CONTROLLED DELIVERY OF ACTIVE AGENTS](#)

Assignee:  **BHATT P** Individual  
**CRUZ E** Individual  
**YAM N** Individual  
**ALZA CORP** Standard company  
Other publications from [ALZA CORP \(ALZA\)](#)...

Inventor:  **BHATT P; CRUZ E; CRUZ E G; YAM N;**

Accession/Update: [2000-365362 / 200380](#)

IPC Code: **A61K 0/00 ; A61K 9/20 ; A61K 9/22 ; A61K 9/24 ; A61K 9/44 ; A61K 31/496 ; A61K 47/02 ; A61K 47/10 ; A61K 47/12 ; A61K 47/14 ; A61K 47/32 ; A61K 47/34 ; A61K 47/38 ; A61K 47/42 ; A61P 25/24 ;**

Derwent Classes: **A96; B07; A11; A25;**

Manual Codes: **A12-V01(Medicines, pharmaceuticals) , B04-C02A(Cellulose and derivatives) , B04-C03C (Polyethers) , B04-N02(Animal protein/polypeptide (No sequence)) , B05-A01B(Group 1a, 2a, 3a excluding K, B, Ra) , B07-D03(Pyrrolidine) , B07-D05(Piperidine) , B12-M03(Emulsion) , B12-M10A (Sustained release) , B14-J01A1(Antidepressant)**

(WO0025753A) Novelty - Use of a flow-promoting layer in a controlled delivery device to minimize drug retention is new.  
Detailed Description - Controlled delivery dosage form () comprises:

- (a) an outer wall which is semipermeable (or partially semipermeable) having an exit orifice formed or formable and which encloses a cavity;
- (b) an expandable layer located in the cavity distal to the exit orifice;
- (c) a drug layer located in the cavity adjacent to the exit orifice and in direct or indirect contact with the expandable layer;
- (d) a flow-promoting layer interposed between the inner surface of the outer wall and at least the external surface of the drug layer.

ACTIVITY - None given.

## MECHANISM OF ACTION - None given.

**Use - I** are particularly useful for controlled release of drugs in a high-loading oral dosage form for e.g. once-a-day administration. Incorporation of a flow-promoting layer enhances the smooth delivery of the drug by providing less friction at the interface between the drug composition and the semipermeable wall.

**Advantage** - The flow-promoting layer provides enhanced delivery of the drug composition reducing the amount of residual drug remaining undispensed in the device. Consequently the convention of adding extra drug to compensate for that undispensed is unnecessary, resulting in dosage forms which are physically smaller and more easy to swallow.

Dwg.0/0

Family:	PDF	Patent	Pub. Date	Derwent Update	Pages	Language	IPC Code
<input checked="" type="checkbox"/> <a href="#">WO0025753A2</a> *			2000-05-11	2000031	56	English	A61K 9/24
Des. States:	(N) AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL II (R) AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW						
Local appls.:	<a href="#">WO1999US0025244</a> Filed:1999-10-26 (99WO-US25244)						
<input checked="" type="checkbox"/> <a href="#">NZ0511465A</a> =			2003-10-31	200380	English		A61K 9/24
Local appls.:	Based on <a href="#">WO00025753</a> (WO 2000025753) NZ1999000511465 Filed:1999-10-26 (99NZ-0511465) <a href="#">WO1999US0025244</a> Filed:1999-10-26 (99WO-US25244)						
<a href="#">JP2002528486W</a> =			2002-09-03	200273	64	English	A61K 9/22
Local appls.:	Based on <a href="#">WO00025753</a> (WO 2000025753) <a href="#">WO1999US0025244</a> Filed:1999-10-26 (99WO-US25244) JP2000000579195 Filed:1999-10-26 (2000JP-0579195)						
<input checked="" type="checkbox"/> <a href="#">ZA0103524A</a> =			2002-07-31	200271	71	English	A61K 0/00
Local appls.:	<a href="#">ZA2001000003524</a> Filed:2001-05-02 (2001ZA-0003524)						
<input checked="" type="checkbox"/> <a href="#">HU0104993A2</a> =			2002-05-28	200249	English		A61K 9/24
Local appls.:	Based on <a href="#">WO00025753</a> (WO 2000025753) HU2001000004993 Filed:1999-10-26 (2001HU-0004993) <a href="#">WO1999US0025244</a> Filed:1999-10-26 (99WO-US25244)						
<input checked="" type="checkbox"/> <a href="#">US2002004860A1</a> =			2002-04-25	200233	25	English	A61K 9/20
Local appls.:	<a href="#">US2001000001116</a> Filed:2001-11-27 (2001US-0001116) Conf of <a href="#">US1999000430837</a> Filed:1999-11-01 (99US-0430837) Provisional <a href="#">US199800106739P</a> Filed:1998-11-02 (98US-106739P)						
<input checked="" type="checkbox"/> <a href="#">US6368626</a> =			2002-04-09	200227	24	English	A61K 9/22

	Provisional US1998000106739P Filed:1998-11-02 (98US-106739P)		
MX1004371A1 =	2002-03-01 200362	Spanish	A61K 9/24
Local appls.: Based on <u>WO00025753</u> (WO 200025753) MX200100004371 Filed:2001-05-02 (2001MX-0004371) WO1999US0025244 Filed:1999-10-26 (99WO-US25244)			
<input checked="" type="checkbox"/> CN1325301A =	2001-12-05 200223	English	A61K 9/24
Local appls.: CN1999000812981 Filed:1999-10-26 (99CN-0812981)			
<input checked="" type="checkbox"/> EP1126827A2 =	2001-08-29 200150	English	A61K 9/24
Des. States: (R) AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE			
Local appls.: Based on <u>WO00025753</u> (WO 200025753) WO1999US0025244 Filed:1999-10-26 (99WO-US25244) EP1999000971310 Filed:1999-10-26 (99EP-0971310)			
KR1075676A =	2001-08-09 200211	English	A61K 9/24
Local appls.: KR20010000705529 Filed:2001-05-02 (2001KR-0705529)			
<input checked="" type="checkbox"/> NO0102168A =	2001-06-13 200141	NO_NO	A61K 9/24
Local appls.: NO2001000002168 Filed:2001-05-02 (2001NO-0002168) WO1999US0025244 Filed:1999-10-26 (99WO-US25244)			
<input checked="" type="checkbox"/> AU0012385A =	2000-05-22 200040	English	A61K 9/24
Local appls.: Based on <u>WO00025753</u> (WO 200025753) AU2000000012385 Filed:1999-10-26 (2000AU-0012385)			

[?INPADOC Legal Status:](#)  
[Claims:](#)  
[Hide claims]

- 1.. A dosage form for an active agent comprising; a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a drug layer located within the cavity adjacent the exit orifice and in direct or indirect contacting relationship with the expandable layer; and a flow-promoting layer interposed between the inner surface of the wall and at least the external surface of the drug layer located within the cavity.
- 2.. The dosage form of Claim 1 wherein the drug layer contains at least 40% by weight of drug based on the weight of the drug layer.
- 3.. The dosage form of Claim 1 wherein the expandable layer comprises an osmotic agent.
- 4.. The dosage form of Claim 3 wherein the flow-promoting layer comprises a material selected from hydrogels, gelatin, polyethylene oxides of less than 1 00,000 MW, hydroxyalkylcelluloses having number average molecular weights of between 9,500 and 1,250,000, and hydroxyalkyl alkylcelluloses having number average molecular weights of between 80,000 to 850,000, and mixtures thereof.

5. The dosage form of Claim 1 wherein the flow-promoting layer is adapted to facilitate release of at least 80% of the drug in the drug layer to the environment of use.
6. An article of manufacture comprising a compressed drug composition overcoated with a flow-promoting layer.
7. The article of Claim 6 comprising an expandable layer in direct or indirect contact with the drug composition and forming a bilayer core with the drug composition, the bilayer core being overcoated with the flow-promoting layer.
8. The article of Claim 7 wherein the flow-promoting layer comprises a material selected from hydrogels, gelatin, polyethylene oxides of less than 1 00,000 MW, Hydroxyalkylcelluloses having number average molecular weights of between 9,500 and 1,250,000, and hydroxyalkyl alkylcelluloses having number average molecular weights of between 80,000 to 850,000, and mixtures thereof.

9. The article of Claim 7 wherein the flow-promoting layer 1 5 comprises an hydroxypropyl cellulose.

10. A method of facilitating the release of a drug from a dosage form comprising a compressed drug composition, a semipermeable wall and a push layer, the method comprising interposing a flow promoting layer between the semipermeable wall and the compressed drug composition.

11. The method of Claim 10 wherein the flow promoting layer comprises a coating on the compressed drug composition prepared from a hydroxyalkyl cellulose and a lower alkanol. †

Application Number	Filed	Original Title
US2001000001116	2001-11-27	CONTROLLED DELIVERY OF ACTIVE AGENTS
US1999000430837	1999-11-01	CONTROLLED DELIVERY OF ACTIVE AGENTS
US1998000106739P	1998-11-02	

[Priority Number:](#)

[Show chemical indexing codes](#)

[Chemical Indexing Codes:](#)

[Ring Index Numbers:](#)

[Extended Polymer Index:](#)

[Specific Compound Numbers:](#)

[Registry Numbers:](#)  
03[M1]:2044U  
05[M2]:2020U

2020U 2044U

[Unlinked Registry Numbers:](#)

[Related Accessions:](#)

Accession Number	Type	Derwent Update	Derwent Title
C2000-110260	C		

1 item found

Device for controlled delivery of high drug-loading compositions includes a flow-promoting layer between the semi-permeable... Page 5 of 5

DEVICE CONTROL DELIVER HIGH DRUG LOAD COMPOSITION FLOW PROMOTE LAYER SEMI PERMEABLE LAYER  
DRUG LAYER

>Title Terms:

DEVICE CONTROL DELIVER HIGH DRUG LOAD COMPOSITION FLOW PROMOTE LAYER SEMI PERMEABLE LAYER  
DRUG LAYER

Pricing Current charges

**Derwent Searches:** Boolean | Accession/Number | Advanced

Data copyright Thomson Derwent 2003

Copyright © 1997-2004  
The Thomson Corporation

[Subscriptions](#) | [Web Seminars](#) | [Privacy](#) | [Terms & Conditions](#) | [Site Map](#) | [Contact Us](#) | [Help](#)

[https://www.delphion.com/derwent/p/dwdetails?pan=2000-365362&pn=W000025753A2&abl=en&s\\_clms=1](https://www.delphion.com/derwent/p/dwdetails?pan=2000-365362&pn=W000025753A2&abl=en&s_clms=1)

10/26/2004